Shopping Cart
- Remove All
- Your shopping cart is currently empty
BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | BR102375 is a non-TZD PPAR γ full agonist (EC50: 0.28 μM) for the treatment of type 2 diabetes. |
In vitro | BR102375 (Compound 18) (10 μM) enhances gene expression related to PPARγ activation and improves glucose uptake with insulin stimulation. Additionally, BR102375 (10 nM, 100 nM, 1 μM; 6 days, 14 days) exhibits concentration-dependent, insulin-sensitive effects on adipogenesis [1]. |
In vivo | BR102375 demonstrates efficacy in a mouse diabetes model, significantly suppressing the rise in random blood glucose levels (75 mpk, p.o., bid) and showing a decent effect on insulin resistance during the Oral Glucose Tolerance Test (OGTT). Additionally, it exhibits results on body weight gain that are nearly identical to those of Pioglitazone [1]. |
Molecular Weight | 554.64 |
Formula | C31H34N6O4 |
Cas No. | 2366255-59-4 |
Relative Density. | 1.28 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.